Membranoproliferative glomerulonephritis risk factors: Difference between revisions
Jump to navigation
Jump to search
Nazia Fuad (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) |
||
| Line 5: | Line 5: | ||
Membranoproliferative glomerulonephritis is associated with several diseases that can be categorized in to different groups. The most relevant conditions are chronic infections, autoimmune diseases, chronic liver disease ([[cirrhosis]] and [[alpha1-antitrypsin deficiency]]), chronic and recovered thrombotic microangiopathies, [[Paraprotein]] deposition diseases, and malignant [[neoplasms]] [[Genetic mutations|genetic mutations.]] | Membranoproliferative glomerulonephritis is associated with several diseases that can be categorized in to different groups. The most relevant conditions are chronic infections, autoimmune diseases, chronic liver disease ([[cirrhosis]] and [[alpha1-antitrypsin deficiency]]), chronic and recovered thrombotic microangiopathies, [[Paraprotein]] deposition diseases, and malignant [[neoplasms]] [[Genetic mutations|genetic mutations.]] | ||
== [[Membranoproliferative glomerulonephritis risk factors|Risk Factors]] == | == [[Membranoproliferative glomerulonephritis risk factors|Risk Factors]] == | ||
Conditions that increase the risk of MPGN incldude: | |||
{| class="wikitable" | {| class="wikitable" | ||
!Risk Factor | ! colspan="2" |Risk Factor | ||
|- | |- | ||
!Immune complex–mediated disease | !Immune complex–mediated disease | ||
| Line 27: | Line 24: | ||
* Bacterial – [[Endocarditis]], infected ventriculoatrial (or jugular) shunt, multiple visceral [[abscesses]], [[leprosy]] | * Bacterial – [[Endocarditis]], infected ventriculoatrial (or jugular) shunt, multiple visceral [[abscesses]], [[leprosy]] | ||
* Protozoal – Malaria, schistosomiasis | * Protozoal – Malaria, schistosomiasis | ||
|- | |- | ||
! | !Thrombotic microangiopathies | ||
| | | | ||
* Healing phase of [[hemolytic uremic syndrome]] (HUS) and/or [[thrombotic thrombocytopenic purpura]] (TTP) | * Healing phase of [[hemolytic uremic syndrome]] (HUS) and/or [[thrombotic thrombocytopenic purpura]] (TTP) | ||
| Line 38: | Line 33: | ||
* [[Sickle cell anemia]] and [[polycythemia]] | * [[Sickle cell anemia]] and [[polycythemia]] | ||
* Transplant [[glomerulopathy]] | * Transplant [[glomerulopathy]] | ||
|- | |- | ||
!Paraprotein deposition diseases | !Paraprotein deposition diseases | ||
| Line 49: | Line 42: | ||
* [[Fibrillary glomerulonephritis]] | * [[Fibrillary glomerulonephritis]] | ||
* [[Monoclonal gammopathy]] of unknown significance | * [[Monoclonal gammopathy]] of unknown significance | ||
|- | |- | ||
!Malignant [[neoplasms]] | !Malignant [[neoplasms]] | ||
| Line 56: | Line 47: | ||
* [[Lymphoma]] | * [[Lymphoma]] | ||
* [[Leukemia]], and carcinoma are associated with a membranoproliferative pattern of renal injury. | * [[Leukemia]], and carcinoma are associated with a membranoproliferative pattern of renal injury. | ||
|} | |} | ||
Revision as of 18:45, 27 July 2018
Overview
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis risk factors On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis risk factors |
|
FDA on Membranoproliferative glomerulonephritis risk factors |
|
CDC on Membranoproliferative glomerulonephritis risk factors |
|
Membranoproliferative glomerulonephritis risk factors in the news |
|
Blogs on Membranoproliferative glomerulonephritis risk factors |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis risk factors |
Membranoproliferative glomerulonephritis is associated with several diseases that can be categorized in to different groups. The most relevant conditions are chronic infections, autoimmune diseases, chronic liver disease (cirrhosis and alpha1-antitrypsin deficiency), chronic and recovered thrombotic microangiopathies, Paraprotein deposition diseases, and malignant neoplasms genetic mutations.
Risk Factors
Conditions that increase the risk of MPGN incldude:
| Risk Factor | |
|---|---|
| Immune complex–mediated disease |
Autoimmune
Chronic infections
|
| Thrombotic microangiopathies |
|
| Paraprotein deposition diseases |
|
| Malignant neoplasms | |
Conditions associated with a membranoproliferative pattern of injury are listed as follows:
- Immune complex–mediated disease
- Idiopathic forms of MPGN or of unknown association[1]
- MPGN type I
- MPGN type II or dense deposit disease and PLD
- MPGN type III
- Autoimmune diseases[2][3][4]
- Systemic lupus erythematosus (SLE)
- Sjögren syndrome
- Rheumatoid arthritis
- Inherited complement deficiencies, in particular, C2 deficiency
- Scleroderma
- Celiac disease
- Chronic infections[5]
- Viral - Hepatitis B, hepatitis C, and cryoglobulinemia type II
- Bacterial - Endocarditis, infected ventriculoatrial (or jugular) shunt, multiple visceral abscesses, leprosy
- Protozoal - Malaria, schistosomiasis
- Other infections - Mycoplasma, Lyme Disease[6]
- Miscellaneous - Chronic liver disease (cirrhosis and alpha1-antitrypsin deficiency)
- Idiopathic forms of MPGN or of unknown association[1]
- Chronic and recovered thrombotic microangiopathies
- Healing phase of hemolytic uremic syndrome and/or thrombotic thrombocytopenic purpura
- Syndromes of circulating antiphospholipid (anticardiolipin) antibodies
- Radiation nephritis
- Nephropathy associated with bone marrow transplantation
- Sickle cell anemia and polycythemia
- Transplant glomerulopathy
- Paraprotein deposition diseases
- Glomerulonephropathies associated with cryoglobulinemia type I
- Waldenström macroglobulinemia
- Immunotactoid glomerulopathy
- Immunoglobulin light chain or heavy chain deposition diseases
- Fibrillary glomerulonephritis
- Genetic mutation
- Deletion of Lys224 in regulatory domain 4 of Factor H
- A study demonstrated that a delegation of a single Lys residue (K224) located within the complement regulatory region in domain 4 of Factor H will resulted in defected complement control . Mutant protein purified from the plasma of patients, so on laboratories test they showed severely reduced cofactor and decay-accelerating activity, as well as diminished attachment to the core complement component C3b. Albeit, cell-binding activity of the mutant protein was normal and comparable to wild-type Factor H.
- Deletion of Lys224 in regulatory domain 4 of Factor H
- Malignant neoplasms
References
- ↑ Fernando C. Fervenza, Sanjeev Sethi and Richard J. Glassock (2012). "Idiopathic membranoproliferative glomerulonephritis: does it exist?". Nephrology Dialysis Transplantation.
- ↑ H. Terence Cook and Matthew C. Pickering (2014). "Histopathology of MPGN and C3 glomerulopathies". NATURE REVIEWS NEPHROLOGY.
- ↑ MICHELINE LEVY, MARIE-CLAIRE GUBLER, MIREILLE SICH, AGNES BEZIAU, AND RENE HABIB (1978). "lmmunopathology Glomerulonephritis of Membranoproliferative with Subendothelial Deposits". clinical immunology and immunopathology.
- ↑ Mårten Segelmark, Thomas Hellmark (2010). "Autoimmune kidney diseases". Elsevier.
- ↑ C Licht, S Heinen, M Jo ́zsi, I Lo ̈schmann, RE Saunders, SJ Perkins, R Waldherr, C Skerka, M Kirschfink, B Hoppe and PF Zipfel (2006). "Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)". International Society of Nephrology.
- ↑ Dimitrios Kirmizis, MD, Georgios Efstratiadis, MD, Dominiki Economidou, MD, Evdoxia Diza-Mataftsi, MD, Maria Leontsini, MD, and Dimitrios Memmos, MD (2004). "MPGN Secondary to Lyme Disease". American Journal of Kidney Diseases. 43.